Status:

COMPLETED

To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects

Lead Sponsor:

Universidad Católica San Antonio de Murcia

Conditions:

Cardiovascular Risk

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Single-blind, double-blind, controlled, randomized clinical trial of two parallel branches depending on the product consumed (experimental product and placebo product) and single-center with the objec...

Detailed Description

Subjects who meet the selection criteria will make a total of two visits to the research laboratory and will carry out the tests established in the protocol. Subsequently, a statistical analysis will ...

Eligibility Criteria

Inclusion

  • Subjects of both sexes (men or women) between 30 and 75 years of age, Caucasian.
  • Present body mass index between 20 and 32 Kg / m2.
  • Presenting fasting serum LDL-cholesterol levels equal to or greater than 110 mg / dL or total serum cholesterol equal to or greater than 180 mg / dL.
  • Volunteers capable of understanding the clinical study and willing to grant written informed consent and to comply with study procedures and requirements.

Exclusion

  • Thyroid dysfunction, infections, or with any type of chronic disease (eg, autoimmune, inflammatory).
  • Subjects who have suffered an ischemic-vascular event in the last months.
  • Subjects in medication and / or nutraceutical treatment for hypertension, diabetes or hyperlipidemia (ex: statins).
  • Subjects in treatment with drugs that due to their narrow therapeutic margin require monitoring of their plasma levels (digoxin, acenocoumarol, warfarin, etc ...).
  • Subjects in treatment that affects body weight or appetite.
  • History of allergic hypersensitivity or poor tolerance to any component of the products under study.
  • Subjects who are carrying out or intend to carry out any type of diet, low-calorie or not, during the study.
  • Subjects who have donated a minimum of 0.5L of blood in the last month Vegetarian subjects.
  • Subjects who have ingested omega 3 and / or 6 supplements in the last three months, (eg, fish oil, evening primrose oil, krill oil, or algae oil).
  • Subjects under treatment with niacin or fibrates.
  • Those subjects with alcohol abuse, or with excessive alcohol consumption (\> 3 glasses of wine or beer / day) were excluded.
  • Patients undergoing major surgery in the last 3 months.
  • Smoking subjects or not, but in any case who have changed their nicotinic habits during their participation in the study.
  • Participation in another clinical trial in the three months prior to the study.
  • Lack of will or inability to comply with clinical trial procedures.
  • Subjects whose condition did not make them eligible for the study according to the researcher's criteria.

Key Trial Info

Start Date :

November 11 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 18 2020

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT04506749

Start Date

November 11 2019

End Date

September 18 2020

Last Update

September 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Catholic University of Murcia

Murcia, Spain, 30107